Reconstituted High-density Lipoprotein Therapy Improves Survival in Mouse Models of Sepsis. (April 2020)

• Record Type: Journal Article
• Authors: Tanaka, Sébastien; Genève, Claire; Zappella, Nathalie; Yong-Sang, Jennyfer; Planesse, Cynthia; Louedec, Liliane; Viranaïcken, Wildriss; Bringart, Matthieu; Montravers, Philippe; Denamur, Erick; Duranteau, Jacques; Couret, David; Meilhac, Olivier
• Is Part Of: Anesthesiology. Volume 132:Number 4(2020)
• Publication Date: 2020-04
• Subjects: Anesthesiology -- Periodicals; Anesthetics -- Periodicals; Anesthesia -- Periodicals; 617.9605
• DOI: 10.1097/ALN.0000000000003155
• Languages: English
• ISSNs: 0003-3022

Abstract

Abstract : Background: High-density lipoproteins exert pleiotropic effects including antiinflammatory, antiapoptotic, and lipopolysaccharide-neutralizing properties. The authors assessed the effects of reconstituted high-density lipoproteins (CSL-111) intravenous injection in different models of sepsis. Methods: Ten-week-old C57BL/6 mice were subjected to sepsis by cecal ligation and puncture or intraperitoneal injection of Escherichia coli or Pseudomonas aeruginosa pneumonia. CSL-111 or saline solution was administrated 2 h after the sepsis. Primary outcome was survival. Secondary outcomes were plasma cell-free DNA and cytokine concentrations, histology, bacterial count, and biodistribution. Results: Compared with saline, CSL-111 improved survival in cecal ligation and puncture and intraperitoneal models (13 of 16 [81%] survival rate vs. 6 of 16 [38%] in the cecal ligation and puncture model; P = 0.011; 4 of 10 [40%] vs. 0 of 10 [0%] in the intraperitoneal model; P = 0.011). Cell-free DNA concentration was lower in CSL-111 relative to saline groups (68 [24 to 123] pg/ml vs. 351 [333 to 683] pg/ml; P < 0.001). Mice injected with CSL-111 presented a decreased bacterial count at 24 h after the cecal ligation and puncture model both in plasma (200 [28 to 2, 302] vs. 2, 500 [953 to 3, 636] colony-forming unit/ml; P = 0.021) and in the liver (1, 359 [360 to 1, 648] vs. 1, 808 [1, 464 to 2, 720] colony-forming unit/ml; P = 0.031). In the pneumonia model, fewer bacteria accumulated in liver and lung of the CSL-111 group. CSL-111–injected mice had also less lung inflammation versus saline mice (CD68+ to total cells ratio: saline, 0.24 [0.22 to 0.27]; CSL-111, 0.07 [0.01 to 0.09]; P < 0.01). In all models, no difference was found for cytokine concentration. 111 Indium bacterial labeling underlined a potential hepatic bacterial clearance possibly promoted by high-density lipoprotein uptake. Conclusions: CSL-111 infusion improved survival in different experimental mouse models of sepsis. It reduced inflammation in both plasma and organs and decreased bacterial count. These results emphasized the key role for high-density lipoproteins in endothelial and organ protection, but also in lipopolysaccharide/bacteria clearance. This suggests an opportunity to explore the therapeutic potential of high-density lipoproteins in septic conditions. Abstract : A human injectable formulation of reconstituted high-density lipoprotein, CSL-111, composed of apolipoprotein A1 and phosphatidylcholines, was tested in three mouse models of sepsis. When administered soon after the insult causing sepsis, CSL-111 improved survival and reduced lung injury, apparent neutrophil activation, and plasma markers of inflammation, but not cytokine concentrations.Supplemental Digital Content is available in the text.